Novel Treatment Option for Neuropathic Pain

Neuralgia Clinical Trial

— NoTOPain  

Official title:

A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02490436
• Other study ID #: SFK3 / 062202_281
• Secondary ID: 2015-001195-2120
• Status: Completed
• Phase: Phase 2
• First received: June 5, 2015
• Last updated: November 7, 2016
• Start date: October 2015
• Est. completion date: October 2016

Study information

• Verified date: November 2016
• Source: Sorlandet Hospital HF
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway: Norwegian Medicines AgencyNorway:National Committee for Medical and Health Research Ethics
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the EGFR-inhibitor cetuximab is better than placebo for the treatment of neuropathic pain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent and anticipated compliance.

• Pain defined as "definite" neuropathic pain, according to the Special Interest Group on Neuropathic Pain guidelines or defined as "probable" NP, according to the guidelines, if the confirmatory test was a positive diagnostic test. Complex regional pain syndrome can be included despite lack of an offending lesion, as long as the "Budapest criteria" are fulfilled

• Neuropathic Pain associated with compressive nerve states (including failed surgery) or CRPS (according to the "Budapest criteria")

• PainDETECT score of at least 13 with average pain intensity of at least 6 /10 over the last four weeks. In addition, a painDETECT pattern indicating that the underlying neuropathic pain is constantly present.

• Worst pain intensity higher than 6 for five of seven days during the screening phase, according to Brif Pain Inventory.

• The patient should be able to distinguish between the neuropathic pain and other pain conditions, including elements of nociceptive pain caused by the same disease process.

• Neuropathic pain duration of between six and thirty months, deemed chronic and likely to be irreversible by clinical history and findings.

• No new or increased neuropathic pain treatment for the last four weeks.

• Standard medical treatments for the patients' underlying condition or neuropathic pain must have been considered or tried and must, according to the opinion of the referring or a consulted pain specialist, be judged to be inappropriate or of insufficient potential efficacy.

• Referring physician agreement to follow up the patient after study completion according to the best possible and available pain treatment and care.

• Women of childbearing potential and men must use an acceptable method of contraception throughout the study, and for 30 days after the last study drug administration.

• Negative pregnancy test within 7 days before each treatment period where appropriate.

• White blood cell count = 3 × 109 with neutrophils = 1.5 × 109/L, platelet count = 100 × 109/L and hemoglobin = 6.21 mmol/L (10 g/dL). Total bilirubin = 1.5 × upper limit of reference range and AST and ALT = 2.5 × upper limit of reference range within the last 28 days before inclusion.

• Aged 18 or above

Exclusion Criteria:

• Neuropathic pain origin in the central nervous system.

• Phantom limb pain or a significant component of nociceptive pain.

• Ascending distal small fiber peripheral neuropathy.

• Patients primarily experiencing pain 'attacks', i.e. pattern of neuropathic pain depicted in picture 3 of the painDETECT.

• Other pain state that may interfere with evaluation of the studied neuropathic pain condition.

• Any underlying medical or psychiatric condition, clinical disorder or laboratory finding, which in the opinion of the investigator may interfere with study objectives.

• Uncontrolled or unstable diabetes.

• Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV), unstable angina pectoris, history of myocardial infarction within the last twelve months, significant arrhythmias

• Severe cerebrovascular disease during the six months prior to inclusion.

• Active and ongoing eye and skin disorders or newly diagnosed gastric ulcer that may interfere with the study treatment.

• History of allergic reaction to any of the study treatment components, red meat or tick bites.

• Previous treatment with any EGFR-pathway inhibitor.

• Women who are pregnant or breastfeeding.

• Participation in another clinical trial within the past 90 days.

• Use of any investigational agent within 90 days prior to day 1 of study drug.

• Known drug abuse/alcohol abuse, legal incapacity or limited legal capacity or any other reason that, in the opinion of the investigator precludes the subject from participating.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Complex Regional Pain Syndromes
• Neuralgia
• Reflex Sympathetic Dystrophy

Intervention

Drug:
• Cetuximab
Randomized cross-over between cetuximab and placebo
• Placebo
Randomized cross-over between cetuximab and placebo

Locations

Country	Name	City	State
Norway	Center for Cancer Treatment, Sorlandet Hospital HF	Kristiansand

Sponsors (3)

Lead Sponsor	Collaborator
Sorlandet Hospital HF	Frontier Science & Technology Research Foundation, Inc., Merck KGaA

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in average neuropathic pain score using an 11-point numeric rating scale.		Days 4-8 after each infusion of cetuximab and placebo	No
Secondary	Comparison of frequency, in all patients on active treatment of at least a 30% reduction of average neuropathic pain score using an 11-point numeric rating scale.		Days 4-8 after each infusion of cetuximab and placebo	No
Secondary	Comparison of frequency in all patients on active treatment of at least a 50% reduction of average neuropathic pain score using an 11-point numeric rating scale.		Days 4-8 after each infusion of cetuximab and placebo	No
Secondary	Comparison of change in average worst neuropathic pain score using an 11-point numeric rating scale.		Days 4-8 after each infusion of cetuximab and placebo	No
Secondary	Comparison of frequency, in all patients on active treatment of at least a 30% reduction of average worst neuropathic pain score using an 11-point numeric rating scale.		Days 4-8 after each infusion of cetuximab and placebo	No
Secondary	Comparison of frequency in all patients on active treatment of at least a 50% reduction of average worst neuropathic pain score using an 11-point numeric rating scale.		Days 4-8 after each infusion of cetuximab and placebo	No
Secondary	Patient Global Impression of Change.		7 days after each infusion.	No
Secondary	Brief Pain Iinventory (short form) interference scores, comparing cetuximab to the placebo.		Days 4-8 after each infusion during treatment periods 1 and 2.	No
Secondary	Brief Pain Iinventory (short form) total scores, comparing cetuximab to the placebo.		Days 4-8 after each infusion during treatment periods 1 and 2.	No
Secondary	2-hourly waking time 11-point numeric rating scale (item #6 from the Brief Pain Inventory) in the first 24 hours and daily thereafter.		2-hourly in first 24 hours after infusion and daily thereafter until end of study (day 86).	No
Secondary	Number of AE and SAE recording		From signing informed consent (within 28 days prior to first study treatment) and until 30 days after the last study infusion.	Yes